FRANKLIN, Mass., March 12, 2013 /PRNewswire/ — Arthrosurface’s Board of Directors announced that Steven Ek was named the Company’s President and Chief Executive Officer, effective November 20, 2012. Mr. Ek is one of the original founders in Arthrosurface and a Director since inception. Mr. Ek has a broad and diverse 25-year career that includes executive positions in operations and product development. Prior to Arthrosurface, Mr. Ek served as Vice President of Engineering at STD Med, Inc., an OEM manufacturer of medical devices and he spent 9 years at Smith & Nephew Endoscopy where he was the Director of R & D.
Steve Tallarida , Chairman of the Board, said, “We are pleased to name Steve Ek as Arthrosurface President and Chief Executive Officer. He knows our products and industry extremely well. Since launching the Company in 2002, Steve has proven to be a highly effective leader, and he has won the confidence of employees, customers and the Board. We are excited about Arthrosurface’s future under Steve and believe our shareholders and customers will benefit from his dedication and focus.”
Mr. Ek said, “I look forward to working with the Board and our people throughout the organization to maximize our strengths, build on our leadership positions and create value for our business. Our ten year anniversary is particularly exciting for our organization and I am very proud of our ability to continuously bring new and unique products to the market.”
Most recently Arthrosurface launched its NanoFx technology. NanoFracture is the next generation stem cell stimulation technology. The new NanoFx system has significant design and technique improvements over traditional microfracture. Professor Peter Behrens , a surgeon collaborator from Hamburg, Germany said, “Microfracture has been around for more than 20 years and despite its success, results were inconsistent. The main reason for this was the variability of the technique. With NanoFx we have now created a procedure that is consistent and reproducible. The channels are much smaller than microfracture, it reaches deeper into the trabecular bone and channel wall compression is avoided which significantly improves bone marrow flow”.
Arthrosurface is an emerging leader in the design and distribution of orthopedic devices for joint preservation, restoration and resurfacing. The Company’s proprietary HemiCAP system is a unique, less invasive technology that can be used to treat a wide variety of joint conditions caused by trauma, injury and disease. The product portfolio is broad and used in all the major joints shoulder, knee, toe and hip. Founded in 2002 and currently based in Franklin, MA, Arthrosurface markets and distributes its products in the US and more than twenty countries around the globe. Through December 31, 2012, over 42,000 HemiCAPs have been implanted worldwide by more than 4,700 surgeons. For more information about Arthrosurface, please visit www.arthrosurface.com.